Schema-Root.org logo

 

  cross-referenced news and research resources about

 AstraZeneca

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Wed. October 26, 2016 reload page to refresh

-
Sanford C. Bernstein set a GBX 5,333 ($65.00) price target on AstraZeneca plc (LON:AZN) in a research note published on Wednesday morning.

AstraZeneca today announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of Lynparza (olaparib) tablets (300mg twice daily) as a monotherapy for the maintenance treatment of platinum-sensitive relapsed, ...
AstraZeneca plc logo AstraZeneca plc (LON:AZN)'s stock had its "neutral" rating reiterated by stock analysts at JPMorgan Chase & Co.
TheStreet's Action Alerts PLUS Portfolio manager Jim Cramer comments on AstraZeneca's ( AZN) recent success in a cancer drug trial.

While four big companies from the pharmaceutical segment have already reported their September quarter results, a handful remain yet to report.
Early action on shares of AstraZeneca PLC (nyse:AZN) puts the stock on today's active list. At press time, the stock had seen a change of -0.62% from the opening price.
United Kingdom based company, AstraZeneca PLC's (AZN)'s latest closing price distance was at -0.39% from the average-price of 200 days while it maintained ...
Today's top gainers include the company AstraZeneca PLC (nyse:AZN) which is in the industry Drug Manufacturers - Major, gaining -0.90% today.
On 10/21/2016, Shares of AstraZeneca PLC (nyse:AZN) closed the trading at a price of $30.72 with the negative change of -0.90%. In the past session.
The FTSE 100 was just below the waterline in afternoon trading on Monday, as investors weighed a sharp drop in monthly UK industrial orders against ...
AstraZeneca PLC ORD (AZNCF)'s shares are attracting intense interest from OTC traders after their share price changed -1.2, reaching a price of $59.7 following a recent trade.
AstraZeneca PLC (nyse:AZN) reported the earnings of $0.83/Share in the last quarter where the estimated EPS by analysts was $0.76/share.
AstraZeneca plc logo AstraZeneca plc (LON:AZN) has been assigned a GBX 4,000 ($48.75) target price by equities research analysts at Goldman Sachs Group Inc. in a report released on Wednesday.
We remind investors that AstraZeneca had received a complete response letter from the FDA for ZS-9 in May 2016. The CRL had cited observations from a pre-approval manufacturing inspection and the receipt of new data, which was yet to be reviewed.
AstraZeneca ($AZN) first bought into ADC Therapeutics as part of a 2013 financing. Then it ponied up intellectual property and a CEO for the Swiss startup from Spirogen, which is a wholly-owned subsidiary of AstraZeneca's MedImmune. Now, it's upped the ...

Synairgen felt the full wrath of the market on AstraZeneca Plc (nyse:AZN) pulling the plug on a phase II trial of its drug targeting severe Asthma.
London--pharmaceutical company AstraZeneca PLC (AZN.LN) said Tuesday the U.S. Food and Drug Administration accepted a complete re-submission of a new drug application for a potential new medicine for treating high potassium levels in the human ...
AstraZeneca Plc (nyse:AZN) has once again reiterated its intention to focus on core therapeutic areas with the signing of a new commercialization agreement with a subsidiary of 3SBio, in China.
"Integrating this site into our existing operations network will provide AstraZeneca and MedImmune, our global biologics research and development arm, with flexible biological manufacturing capacity to quickly bring new innovative treatments to ...
AstraZeneca has sold off licensing rights to its diabetes drugs Byetta and Bydureon in China, pocketing $50 million upfront from a subsidiary of the Chinese 3SBio as it continues to shed non-core assets.
London--Drug development company Synairgen PLC (SNG.LN) said Wednesday that AstraZeneca PLC (AZN.LN) has decided to stop the clinical trial of asthma treatment drug AZD9412, or inhaled interferon beta-1a.
Thousand Oaks biotech giant Amgen continued its Colorado exit plans recently as it sold a Longmont, Colo., facility to London-based pharmaceutical and biotech company AstraZeneca for $64.5 million. Amgen built the 692,000-square-foot facility in the ...
PhaRMA giant AstraZeneca is shelling out $64.5 million for Amgen's facility in Longmont, CO, further expanding its footprint on the outskirts of Denver.
Last week, AstraZeneca's (nyse:AZN) blood thinning drug Brilinta failed a drug trial when it was unsuccessful in improving symptomatic peripheral artery disease patients relative to Plavix (i.
A second Colorado site in Longmont was also put up for sale by Amgen, and yesterday AstraZeneca confirmed it is the buyer of the 692,000 sq ft site.
AstraZeneca plc (ADR) (nyse:AZN) is scheduled to report its third-quarter earnings data on November 10. Merrill Lynch analyst Sachin Jain and team reiterated a Buy rating on the company's stock ahead of the results while lowering their earnings ...
AstraZeneca PLC (nyse:AZN) reported the earnings of $0.83/Share in the last quarter where the estimated EPS by analysts was $0.76/share.
AstraZeneca plc logo AstraZeneca plc (LON:AZN) has been assigned a GBX 4,000 ($48.75) target price by equities research analysts at Goldman Sachs Group Inc. in a report released on Wednesday.
AstraZeneca, a global, science-led biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted a complete re-submission of a New Drug Application (NDA) for sodium zirconium cyclosilicate (ZS-9), a potential new ...
We remind investors that AstraZeneca had received a complete response letter from the FDA for ZS-9 in May 2016. The CRL had cited observations from a pre-approval manufacturing inspection and the receipt of new data, which was yet to be reviewed.
AstraZeneca ($AZN) first bought into ADC Therapeutics as part of a 2013 financing. Then it ponied up intellectual property and a CEO for the Swiss startup from Spirogen, which is a wholly-owned subsidiary of AstraZeneca's MedImmune. Now, it's upped the ...
Synairgen felt the full wrath of the market on AstraZeneca Plc (nyse:AZN) pulling the plug on a phase II trial of its drug targeting severe Asthma.
London--pharmaceutical company AstraZeneca PLC (AZN.LN) said Tuesday the U.S. Food and Drug Administration accepted a complete re-submission of a new drug application for a potential new medicine for treating high potassium levels in the human ...
AstraZeneca PLC ORD (AZNCF)'s shares have attracted interest from OTC investors as their share price moved 0.35, reaching a price of $60.9 after recent trading.
AstraZeneca plc logo AstraZeneca plc (LON:AZN) had its price objective hoisted by research analysts at Jefferies Group from GBX 5,800 ($71.78) to GBX 6,000 ($74.26) in a research note issued to investors on Thursday.
AstraZeneca PLC logo TheStreet downgraded shares of AstraZeneca PLC (NYSE:AZN) to a hold rating in a research note released on Friday.
AstraZeneca Plc (nyse:AZN) has once again reiterated its intention to focus on core therapeutic areas with the signing of a new commercialization agreement with a subsidiary of 3SBio, in China.
Respiratory drug discovery company Synairgen (LSE: SNG) says it has been advised by its development partner AstraZeneca (LSE: AZN) that it has "decided to stop the Phase IIa trial of AZD9412 based on an interim analysis, where an overall very low ...
AstraZeneca has sold off licensing rights to its diabetes drugs Byetta and Bydureon in China, pocketing $50 million upfront from a subsidiary of the Chinese ...
London--Drug development company Synairgen PLC (SNG.LN) said Wednesday that AstraZeneca PLC (AZN.LN) has decided to stop the clinical trial of asthma treatment drug AZD9412, or inhaled interferon beta-1a.
AstraZeneca ($AZN) has halted a Phase IIa trial of the severe asthma drug it licensed from Synairgen (LON:SNG). The Big PhaRMA took action after an interim analysis raised doubts about whether the study could deliver meaningful data against its primary ...
PhaRMA giant AstraZeneca is shelling out $64.5 million for Amgen's facility in Longmont, CO, further expanding its footprint on the outskirts of Denver.
Last year , AstraZeneca snapped up the LakeCentre facility in Boulder, Colorado three years after Amgen halted operations as part of a cost-saving network optimisation programme.
Last week, AstraZeneca's (nyse:AZN) blood thinning drug Brilinta failed a drug trial when it was unsuccessful in improving symptomatic peripheral artery disease patients relative to Plavix (i.
AstraZeneca (nyse:AZN) is in the news these days due to its failed drug trials and the decision to offer a two drug treatment for lung cancer.
AstraZeneca ($AZN) has posted an update on a Phase I/II trial of its anti-PD-L1 monoclonal antibody durvalumab in non-small cell lung cancer (NSCLC).
Drug company AstraZeneca purchased a biotech drug manufacturing plant on 228 acres in Longmont, spending $64.5 million buying the site from Amgen Inc. a ...
London--AstraZeneca PLC (AZN.LN) said Friday has sold its rights outside the U.S. for nasal spray Rhinocourt Aqua to Johnson & Johnson JNJ, -2.18% affiliate Cilag GmbH International for $330 million.


spacer

 


 


 


 


 


schema-root.org

     astrazeneca

pharmaceutical industry:
     ariad
     astrazeneca
     baxter
     eli lilly
     glaxosmithkline
     merck
     mylan
     novartis
     pfizer
     products
     research
     takeda
     upjohn
     valeant